J&J Stops Alzheimer's Study as Drug Proves Ineffective in Slowing Disease Progression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 25 2025
0mins
Source: Benzinga
Johnson & Johnson's Study Results: The Phase 2b AuTonomy study of posdinemab for early Alzheimer's disease did not achieve statistical significance in slowing clinical decline, leading to its discontinuation.
FDA Designation and Potential: Posdinemab received Fast Track designation from the FDA, showing potential to target phosphorylated tau in Alzheimer's patients, but its recent failure raises concerns for future Alzheimer's drug developments.
Novo Nordisk's Trial Findings: Novo Nordisk's phase 3 trials for semaglutide in early-stage Alzheimer's disease also failed to show superiority over placebo in reducing disease progression.
Market Reaction: Following the news, Johnson & Johnson's stock rose to a new 52-week high, trading at $206.99, reflecting investor sentiment despite the study setback.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 224.440
Low
190.00
Averages
218.50
High
240.00
Current: 224.440
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Patients as Partners® Europe Conference Set for May 2026 in London
- Conference Themes and Speakers: The 10th annual Patients as Partners® Europe conference will take place on May 19-20, 2026, at the Royal National Hotel in London, focusing on how patient involvement enhances drug development value and accessibility, featuring speakers from Sanofi and Novartis.
- Industry Integration and Collaboration: This event signifies a shift from patient-centricity to true partnership, bringing together pharma companies, patients, and service providers to tackle complex challenges and enhance the impact of drug development.
- Key Topics and Case Studies: The conference will address critical topics such as integrated patient engagement, patient experience data, and patient preferences in clinical trials, with participation from major pharma companies like Pfizer, Roche, and Johnson & Johnson showcasing the latest industry success stories.
- Stakeholder Engagement: Co-produced with patients, the R&D industry, academia, and nonprofit organizations, Patients as Partners® Europe aims to meet the needs of all stakeholders, advancing patient involvement, access, and diversity throughout the clinical development continuum.
Continue Reading
Visa and Johnson & Johnson: Future Dividend Giants
- Visa's Market Outlook: With a current market cap of $623 billion, Visa is projected to reach a trillion-dollar valuation within seven years at a 7% CAGR, driven by its leadership in global payment processing and robust revenue growth.
- Dividend Growth Potential: Since going public in 2008, Visa has consistently increased its dividends, with a current payout ratio of only 24%, indicating strong capacity for future dividend hikes while maintaining ample cash flow for other investments.
- Johnson & Johnson's Successful Transformation: Currently valued at $530 billion, Johnson & Johnson needs a 9.5% CAGR to reach a trillion-dollar valuation in seven years; despite recent challenges, its strategic shift away from low-growth consumer health and expansion into medtech signals strong growth potential.
- Innovation-Driven Growth: Johnson & Johnson's entry into robotic-assisted surgery with its Ottava device, nearing U.S. clearance, suggests that new products over the next few years will boost revenue and profits, while maintaining a reasonable payout ratio of 46.59% ensures sustained dividend growth.
Continue Reading